ServiziMenu principaleHome
You are here: Home > Events > Past events > 2023 > Adverse Events Management and Interstitial Lung Disease (ILD) Detection Online Course
Download page in PDF

Adverse Events Management and Interstitial Lung Disease (ILD) Detection Online Course

31.03.2023  -  01.04.2023




Alfredo Addeo, CH - Aleksandra Filipovic, UK


31 March - 01 April 2023


Interstitial Lung Disease (ILD) is an issue for many cancers and cancer treatments. With the development of immunotherapies, it has become a focus of attention, but it is an historical issue related to radiation, busulfan and bleomycin.

Many treatments in various disease areas have ILD as a potential toxicity. Early diagnosis is crucial to avoid irreversible damage or even death of the patient.

Following the Task Force (held on April 25), the results of which have been summarised in a scientific article published on the Cancerworld magazine, the ILD Project foresaw the following steps:

- Five Podcasts, consisting of short contributions on the topic by Task Force experts, will be developed. The podcasts will be free of charge and accessible to the audience by registering on SPCC's OncoCorner e-learning platform.

- Three Educational Webinars free of charge and accessible to the audience by registering on SPCC's OncoCorner e-learning platform.

The online course, final step of the project, summarised the main topics from the previous Task Force and webinars, soon on-demand via OncoCorner.

More information on the project are available via https://www.spcc.net/en/projects/adverse-events-management-and-interstitial-lung-disease-ild-detection-project/1-5163-0-

Course Goals

The aim of this project is to expand awareness and knowledge among HPCs about:

  • The frequency of ILD with various oncological treatments;
  • Patients at major risk and methods if any to avoid ILD;
  • The appropriate methods to diagnose ILD early, with or without sophisticated radiological methods;
  • Treatment of ILD and possible reinstatement of the oncological drug.

Target Group

HCP’s - Medical oncologists – Haematologists - Radiation oncologists – Pulmonologists - Radiologists

Course Format

The course was held online with the participation of world-renowned experts, some of them already involved in the Task Force, podcasts and webinars.
The material is now available on-demand via https://www.oncocorner.net/online-events/51#prog 

Course Content

The event consisted of 2 consecutive days of live sessions.


Organising Secretariat

Sharing Progress in Cancer Care
Via Vincenzo Vela, 6
6500 Bellinzona – Switzerland

Martina Radice
martina.radice@spcc.net - Tel: +41 76 325 92 92

Continuing Medical Education Accreditation

Application for CME accreditation has been submitted to the Accreditation Council of Oncology in Europe (ACOE).

The programme was recognised as being of high quality from both a scientific and didactic point of view and was awarded 4 CME credits.

Participants will be issued a certificate of attendance (minimum attendance: 75% of the entire course). An online evaluation questionnaire and learning assessment test will need to be completed in order to get the certificate that will be issued by email.


Sharing Progress in Cancer Care wishes to express its appreciation to AstraZeneca and Daiichi Sankyo for their unrestricted educational grants.


31 March

15:30Day 1
 15:30Welcome and introduction
Alfredo Addeo, CH - Aleksandra Filipovic, UK
 15:45ILD and cancer drugs
Aleksandra Filipovic, UK
 16:00Practical approach to diagnose interstitial lung disease (ILD): tips from the pneumologist to the oncologist
Elisabeth Bendstrup, DK
 16:20Practical approach to diagnose ILD: tips from the radiologist to the oncologist
Cornelia Schaefer-Prokop , DE
 16:40ILDs in GI malignancies treated with novel anti-HER2 ADC
Zev Wainberg, US
 17:00Educational session discussion and Q&A
Alfredo Addeo, CH - Elisabeth Bendstrup, DK - Aleksandra Filipovic, UK - Cornelia Schaefer-Prokop , DE - Zev Wainberg, US
Alfredo Addeo, CH - Aleksandra Filipovic, UK

01 April

14:30DAY 2
 14:30Welcome and introduction
Alfredo Addeo, CH - Aleksandra Filipovic, UK
 14:40Summary of Webinar 2: - Interstitial lung disease (ILD) and monoclonal antibodies, mTOR inhibitors and CDK4/6 inhibitors: ADCs or T-DXd and other ADCs
Veronique Dieras, FR
 15:00Interstitial lung disease practical management: can you restart the drug if it was giving benefit?
Antonio Marra, IT
 15:20ILDs seen with checkpoint inhibitors
Bruno Bockorny, US
 15:40ILD and Radiation Oncology
Suresh Senan, NL
 16:00Educational session discussion and Q&A
Alfredo Addeo, CH - Bruno Bockorny, US - Veronique Dieras, FR - Aleksandra Filipovic, UK - Antonio Marra, IT - Suresh Senan, NL
Alfredo Addeo, CH - Aleksandra Filipovic, UK


Alfredo Addeo, Oncology Division, University Hospital Geneva, Switzerland
Elisabeth Bendstrup, Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark
Bruno Bockorny, Clinical Director, Phase 1 Oncology Program Beth at Israel Deaconess Medical Center, Boston, USA
Veronique Dieras, Senior Medical Oncologist at Centre Eugène-Marquis, Rennes, France
Aleksandra Filipovic, Imperial College London, United Kingdom
Antonio Marra, European Institute of Oncology IRCSS, Early Drug Development for Innovative Therapies Dept., Milan, Italy
Cornelia Schaefer-Prokop, Radiologist at Meander Medical Centre, Amersfoort, The Netherlands
Suresh Senan, Amsterdam University Medical Centers, VUmc location, Amsterdam, The Netherlands
Zev Wainberg, Professor of Medicine at UCLA and co-director of the UCLA GI Oncology Program, Los Angeles, USA